Antimicrobial Susceptibility of Genital Ureaplasma spp. and Mycoplasma hominis
- 1Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, İzmir University of Economics, Medical Point Hospital, İzmir 35330, Türkiye
- 2Department of Obstetrics and Gynecology, İzmir University of Economics Medical Point Hospital, İzmir 35575, Türkiye
Abstract
Background/Objectives: Ureaplasma spp. and Mycoplasma hominis may be detected as colonizers or in association with urogenital disease, while antimicrobial resistance and methodological variability complicate interpretation of susceptibility data. This study aimed to characterize local in vitro phenotypic antimicrobial susceptibility patterns of Ureaplasma spp. and M. hominis and to explore organism- and sex-associated differences. Methods: In this retrospective microbiological surveillance study, 242 patients were tested between April 2023 and April 2025 using the Mycoplasma IES commercial culture-based system. Specimens with insufficient growth or mixed Ureaplasma spp./M. hominis growth were excluded, leaving 176 single-organism-positive patients with valid susceptibility results. Eleven antimicrobial agents were evaluated using the assay-defined categorical interpretation. Results: Ureaplasma spp. were detected in 145 patients (82.4%) and M. hominis in 31 (17.6%). Phenotypic resistance was highest for clindamycin (99.4%), ciprofloxacin (91.5%), and ofloxacin (64.2%), whereas susceptibility was high for josamycin (99.4%), minocycline (98.9%), pristinamycin (98.9%), and tetracycline (84.1%). M. hominis showed substantially greater resistance than Ureaplasma spp. to clarithromycin, erythromycin, roxithromycin, and levofloxacin (all p < 0.001). Unadjusted sex differences in macrolide resistance were considered exploratory because M. hominis occurred almost exclusively among women. Conclusions: The findings provide local assay-derived phenotypic surveillance data and demonstrate marked organism- and antimicrobial-specific variation. Because the commercial assay does not distinguish U. urealyticum from U. parvum and reference MIC confirmation was not performed, the results should be interpreted within these methodological limitations and should not be used alone to infer clinical treatment efficacy.
Related
- Antimicrobial practices for Mycoplasma infections in cattle: A survey of veterinary practitioners in light of current scientific evidence and national guidelines
- Economic Barriers to Antimicrobial Susceptibility Testing as a Structural Contributor to Antimicrobial Resistance in Low- and Middle-Income Countries: A Narrative Review.
- A call for sharing phenotypic antimicrobial susceptibility data alongside bacterial genome sequence data in public archives
- Rapid identification and antimicrobial susceptibility testing of pathogenic microorganisms from positive blood cultures
- Artificial Intelligence in the Fight Against Antimicrobial Resistance: Applications in Diagnosis, Susceptibility Prediction, Precision Dosing, and Antibiotic Discovery.
BibTeX
@article{bulgak2026antimicrobial,
title = {{Antimicrobial Susceptibility of Genital Ureaplasma spp. and Mycoplasma hominis}},
author = {Mirkan Bulğak and Pınar Tuğçe Özer},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15208129},
url = {https://www.mdpi.com/2077-0383/15/20/8129},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Antimicrobial Susceptibility of Genital Ureaplasma spp. and Mycoplasma hominis
AU - Mirkan Bulğak
AU - Pınar Tuğçe Özer
PY - 2026
DA - 2026/10/20
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15208129
UR - https://www.mdpi.com/2077-0383/15/20/8129
AB - Background/Objectives: Ureaplasma spp. and Mycoplasma hominis may be detected as colonizers or in association with urogenital disease, while antimicrobial resistance and methodological variability complicate interpretation of susceptibility data. This study aimed to characterize local in vitro phenotypic antimicrobial susceptibility patterns of Ureaplasma spp. and M. hominis and to explore organism- and sex-associated differences. Methods: In this retrospective microbiological surveillance study, 242 patients were tested between April 2023 and April 2025 using the Mycoplasma IES commercial culture-based system. Specimens with insufficient growth or mixed Ureaplasma spp./M. hominis growth were excluded, leaving 176 single-organism-positive patients with valid susceptibility results. Eleven antimicrobial agents were evaluated using the assay-defined categorical interpretation. Results: Ureaplasma spp. were detected in 145 patients (82.4%) and M. hominis in 31 (17.6%). Phenotypic resistance was highest for clindamycin (99.4%), ciprofloxacin (91.5%), and ofloxacin (64.2%), whereas susceptibility was high for josamycin (99.4%), minocycline (98.9%), pristinamycin (98.9%), and tetracycline (84.1%). M. hominis showed substantially greater resistance than Ureaplasma spp. to clarithromycin, erythromycin, roxithromycin, and levofloxacin (all p < 0.001). Unadjusted sex differences in macrolide resistance were considered exploratory because M. hominis occurred almost exclusively among women. Conclusions: The findings provide local assay-derived phenotypic surveillance data and demonstrate marked organism- and antimicrobial-specific variation. Because the commercial assay does not distinguish U. urealyticum from U. parvum and reference MIC confirmation was not performed, the results should be interpreted within these methodological limitations and should not be used alone to infer clinical treatment efficacy.
SN - 2077-0383
ER -